Nyxoah to Release First Quarter 2023 Financial Results on May 16, 2023 2-05-2023, 03:30

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

Curium and PIUR IMAGING Announce Thyroid Imaging Partnership in Germany to Enable Tomographic 3D Ultrasound Solutions 25-10-2023, 18:33